Belatacept Maintenance Immunosuppression for Calcineurin Inhibitor Sparing or Avoidance in Pancreas Transplant Recipients With Progressive Renal or Renal Allograft Dysfunction.

ABSTRACT: Belatacept may be used to spare or replace calcineurin inhibitors (CNI) to preserve renal function. Use in pancreas transplant (PTx) is limited by increased risk of pancreas rejection. This retrospective analysis included all PTxs performed between 2004 and 2023. A 1:2 case/control analysis was performed to identify predictors of belatacept use and compare allograft and patient survival. Of 731 PTxs, 21 (3%) started belatacept (eight simultaneous pancreas and kidney (SPK), three pancreas after kidney (PAK), and 10 pancreas transplant alone (PTA). At 1 year, Δ estimated glomerular filtration rate (eGFR) was +7% SPK, -15% PAK, and +32% PTA. Case-control analysis found no demographic predictors for belatacept except older recipient age for PTA. No difference in median kidney, pancreas, or pat

SUBMITTER: Chen JM 

PROVIDER: S-EPMC12457987 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature